Tokyo - Delayed Quote JPY

Daiichi Sankyo Company, Limited (4568.T)

5,340.00

-60.00

(-1.11%)

As of 11:35 AM GMT+9. Market Open.

ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy

TOKYO & BASKING RIDGE, N.J., June 02, 2024--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy

Business Wire 15 days ago

DSKYF

DSNKY
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902. Both rilvegostomi

PR Newswire 18 days ago

CGEN

DSKYF

DSNKY
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.

Zacks 19 days ago

AZN

4568.T
-1.11%
ALXO
Why Is AstraZeneca Stock Trading Lower On Tuesday?

On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial. Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated wi

Benzinga 20 days ago

AZN

4568.T
-1.11%
AstraZeneca and Daiichi Sankyo’s ADC improves survival in NSCLC trial

In a prespecified patient subgroup, datopotamab deruxtecan showed a clinically meaningful improvement in OS versus docetaxel.

Clinical Trials Arena 21 days ago

AZN

4568.T
-1.11%
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

TOKYO & BASKING RIDGE, N.J., May 27, 2024--Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. Survival results did not reach statistical signific

Business Wire 21 days ago

DSKYF

DSNKY
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO

BASKING RIDGE, N.J., May 21, 2024--Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO

Business Wire 27 days ago

DSKYF

DSNKY
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore

This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.

Zacks 28 days ago

AZN

PFE

4568.T
-1.11%
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt

Benzinga last month

ESPR

4568.T
-1.11%
AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement

AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement

PREMIUM
MT Newswires last month

AZN

4568.T
-1.11%
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06

Business Wire last month

DSKYF

DSNKY
AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'

AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.

Yahoo Finance last month

WXIBF

WXXWY

DSKYF
Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.

Zacks 2 months ago

ARAY

4568.T
-1.11%
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Zacks 2 months ago

4568.T
-1.11%
ADMA
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor

On Friday, the FDA approved Daiichi Sankyo Ltd’s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indicat

Benzinga 2 months ago

AZN

4568.T
-1.11%
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.

Zacks 2 months ago

AZN

ADMA

4568.T
-1.11%
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

TOKYO & BASKING RIDGE, N.J., April 06, 2024--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors

Business Wire 2 months ago

AZN

AZNCF

DSKYF
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Zacks 2 months ago

4568.T
-1.11%
ADMA
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Business Wire 2 months ago

DSKYF

DSNKY

MRK
AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.

Zacks 2 months ago

AZN

4568.T
-1.11%
ADMA

Performance Overview

Return	4568.T	Nikkei 225
YTD	+38.75%	+15.06%
1-Year	+11.63%	+14.23%
3-Year	+118.61%	+32.94%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daiichi Sankyo Company, Limited (4568.T)

ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal

Why Is AstraZeneca Stock Trading Lower On Tuesday?

AstraZeneca and Daiichi Sankyo’s ADC improves survival in NSCLC trial

Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO

AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

Performance Overview